Profile
| Metric | Value |
|---|---|
| Full Name | EyePoint Pharmaceuticals, Inc. |
| Ticker | NASDAQ: EYPT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | eyepointpharma.com |
| Employees | 165 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $16.86 | |
| Price, 1D Change | -3.27% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.09 | |
| Revenue | $43M | |
| Revenue, 1Y Change | -5.97% | |
| EPS | -$2.32 | |
| EPS, 1Y Change | -27.75% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:10 | |
| Next Split | N/A | N/A |
| Last Ticker Change | PSDV | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.32 | |
| EPS Estimate | -$3.01 | |
| EPS Est. Change | -29.69% | |
| Revenue | $43.27M | |
| Revenue Estimate | $31.77M | |
| Revenue Est. Change | -26.58% | |
| Current Price | $16.86 | |
| Price Target | - | $33.00 |
| Price Tgt. Change | - | +95.73% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$1.94 | -$1.82 | +6.20% | |
| -$2.17 | -$2.32 | -7.33% | |
| -$3.01 | N/A | -29.69% | |
| -$2.84 | N/A | -22.35% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $40.67M | $46.02M | +13.15% | |
| $42.55M | $43.27M | +1.71% | |
| $31.77M | N/A | -26.58% | |
| $4.76M | N/A | -89.00% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +94.24% | |
| Price, 3Y | +417.18% | |
| Market Cap, 1Y | +135.56% | |
| Market Cap, 3Y | +1,156.22% | |
| Revenue, 1Y | -5.97% | |
| Revenue, 3Y | +17.15% | |
| EPS, 1Y | -27.75% | |
| EPS, 3Y | -14.44% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $16.86 | |
| SMA 200 | $10.83 | |
| SMA 200 vs Price | -35.77% | |
| SMA 50 | $14.84 | |
| SMA 50 vs Price | -11.97% | |
| Beta | 1.09 | |
| ATR | $0.96 | |
| 14-Day RSI | 51.32 | |
| 10-Day Volatility | 55.34% | |
| 1-Year Volatility | 77.15% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $43.27M | |
| EPS | -$2.32 | |
| Gross Profit | $39.56M | |
| Gross Margin | 91.42% | |
| Operating Profit | -$145.85M | |
| Operating Margin | -337.06% | |
| Net Income | -$130.87M | |
| Net Margin | -302.43% | |
| EBITDA | -$129.23M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.07 | |
| 7.81 | ||
| 7.77 | ||
| - | ||
| 2 | ||
| 7.33 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 32.97 | ||
| 6.97 | ||
| -5.62 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $336.50M | |
| $370.91M | ||
| $418.47M | ||
| $383.31M | ||
| $81.96M | ||
| $49.05M | ||
| Total Debt | $23.11M | |
| $1.25M | ||
| $11.72M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $189.13M | ||
| $185.42M | ||
| $3.71M | ||
| $52.49M | ||
| $1.54M | ||
| $0.00 | ||
| $90.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$126.23M | ||
| -$219.36M | ||
| $164.02M | ||
| Capex | $4.05M | |
| -$130.28M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| RBC Capital | → | |
| Chardan Capital | → | |
| HC Wainwright & Co. | → | |
| RBC Capital | ||
| HC Wainwright & Co. | → | |
| Mizuho | → | |
| Chardan Capital | → | |
| HC Wainwright & Co. | → | |
| Chardan Capital | → | |
| Chardan Capital | → |
Analyst sentiment
Institutional ownership
Screeners with EYPT
Data Sources & References
- EYPT Official Website eyepointpharma.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1314102/000119312525269471/0001193125-25-269471-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1314102/000095017025034601/0000950170-25-034601-index.htm
- EYPT Profile on Yahoo Finance finance.yahoo.com/quote/EYPT
- EYPT Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/eypt
FAQ
What is the ticker symbol for EyePoint Pharmaceuticals, Inc.?
The ticker symbol for EyePoint Pharmaceuticals, Inc. is NASDAQ:EYPT
Does EyePoint Pharmaceuticals, Inc. pay dividends?
No, EyePoint Pharmaceuticals, Inc. does not pay dividends
What sector is EyePoint Pharmaceuticals, Inc. in?
EyePoint Pharmaceuticals, Inc. is in the Healthcare sector
What industry is EyePoint Pharmaceuticals, Inc. in?
EyePoint Pharmaceuticals, Inc. is in the Biotechnology industry
What country is EyePoint Pharmaceuticals, Inc. based in?
EyePoint Pharmaceuticals, Inc. is headquartered in United States
When did EyePoint Pharmaceuticals, Inc. go public?
EyePoint Pharmaceuticals, Inc. initial public offering (IPO) was on January 27, 2005
Is EyePoint Pharmaceuticals, Inc. in the S&P 500?
No, EyePoint Pharmaceuticals, Inc. is not included in the S&P 500 index
Is EyePoint Pharmaceuticals, Inc. in the NASDAQ 100?
No, EyePoint Pharmaceuticals, Inc. is not included in the NASDAQ 100 index
Is EyePoint Pharmaceuticals, Inc. in the Dow Jones?
No, EyePoint Pharmaceuticals, Inc. is not included in the Dow Jones index
When was EyePoint Pharmaceuticals, Inc. last earnings report?
EyePoint Pharmaceuticals, Inc.'s most recent earnings report was on November 5, 2025
When does EyePoint Pharmaceuticals, Inc. report earnings?
The next expected earnings date for EyePoint Pharmaceuticals, Inc. is March 4, 2026